GLP-1 · 6 min read
GLP-1 medications and menopause: a clinical perspective
Published April 15, 2026 · Last updated May 10, 2026
GLP-1 receptor agonists — semaglutide and tirzepatide most commonly — produce meaningful weight loss in patients who meet criteria. In menopause, where metabolism shifts and visceral fat accumulates, they can be especially useful.
How we use them
- Always paired with resistance training to protect muscle mass
- Adequate protein — 1.2–1.6 g/kg body weight per day
- Coordinated with HRT when indicated
- Slow, careful dose titration to manage GI side effects
GLP-1 medications are tools, not magic. The patients who do best are the ones who change behavior alongside the medication.
Menopause weight gain has a cause — and a protocol.
The metabolic slowdown of menopause is driven by estrogen-related insulin resistance, cortisol, and muscle loss. The kindr Metabolic Reset addresses all three.
Medically reviewed by Kindr Health Clinical Team
Kindr Health Inc. — Editorial & Clinical Team (physician-supervised)
NPI 1609792902 · Last reviewed: July 3, 2026
More on weight & metabolic health
- Midlife weight gainSymptom
- Menopause & weight gainArticle
- SemaglutideMedication
- TirzepatideMedication
- GLP-1 weight careService
- Metabolic health serviceService
Continue across the Kindr entity graph
Related evidence, peptides, and clinical tools on the same topic.
- Is HRT safe?Journal
- Menopause & weight gainJournal
- When to start HRTJournal
- SemaglutidePeptide
- Menopause HRT serviceMedication
- TirzepatidePeptide
Sources
- STEP 1 — NEJM 2021 — www.nejm.org/doi/full/10.1056/NEJMoa2032183
- SURMOUNT-1 — NEJM 2022 — www.nejm.org/doi/full/10.1056/NEJMoa2206038
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.